September 2009
BioWorld Insight;9/7/2009, Vol. 17 Issue 36, p6
The article offers news related to biotechnology financings and deals in the U.S. It relates that Eurand NV has obtained approval of its Zenpep (pancrelipase) delayed-release capsules from the Food and Drug Administration (FDA). It mentions that Algeta ASA has received an 800 million dollars deal for its Phase III drug alpharadin from Bayer Schering Pharma AG. It notes that Immunomedics Inc. has raised over 151.1 million dollars.


Related Articles

  • Other News To Note.  // BioWorld Today;7/23/2010, Vol. 21 Issue 141, p3 

    This section offers news briefs on the biotechnology industry. Two agreements were concluded by Algeta ASA for the manufacture and supply for future commercial sale of Alpharadin (radium-223). A notice was received by Antigenics Inc. from Nasdaq on the firm's failure to meet the 1 U.S. dollar...

  • CLINIC ROUNDUP.  // BioWorld Today;6/19/2008, Vol. 19 Issue 119, p10 

    This section offers news briefs on clinical trials in the biotechnology industry worldwide. Algeta ASA has began patient recruitment in a pivotal Phase III study of targeted therapeutic Alpharadin in advanced, hormone-refractory prostate cancer. Biopure Corp. announced that the U.S. Naval...

  • US FDA APPROVES XOFIGO (RADIUM-223 DICHLORIDE).  // Worldwide Biotech;Jun2013, Vol. 25 Issue 6, p2 

    The article reports on the approval of the Food and Drug Administration on the pharmaceutical company Algeta ASA's Xofigo (radium-223 dichloride) injection for the treatment of patients with astration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic...

  • EURAND'S SUPPLIER SUBMITS RESPONSE TO FDA ON EUR-1008.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p8 

    The article reports on an announcement made by specialty pharmaceutical company Eurand NV that its raw material supplier has filed its response to questions relating to the Drug Master File (DMF) raised by the U.S. Food and Drug Administration (FDA) for EUR-1008, an innovative pancreatic enzyme...

  • QUESTCOR INITIATES QSC-001 CLINICAL PROGRAM.  // Biotech Business;Jan2007, Vol. 20 Issue 1, p5 

    The article reports that Questcor Pharmaceuticals Inc. has initiated patient dosing of QSC-001 with the U.S. Food and Drug Administration. QSC-001 is an orally disintegrating tablet (ODT) formulation of hydrocodone bitartrate and acetaminophen for treating moderate to moderately severe pain....

  • CLINIC ROUNDUP.  // BioWorld Today;1/15/2009, Vol. 20 Issue 9, p2 

    This section offers news briefs related to the pharmaceutical industry. Algeta ASA that its BC1-04 Phase II clinical trial of Alpharadin for treating bone metastases in patient with hormone-refractory prostrate cancer showed strong evidence that the drug can prolong patient survival time. A U.S....

  • Algeta's Xofigo Wins FDA Nod Ahead of Schedule. Shaffer, Catherine // BioWorld Today;5/16/2013, Vol. 24 Issue 94, p1 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of the therapeutic agent Xofigo developed by Algeta ASA and Bayer AG for castration-resistant prostate cancer. The approval is based on data showing that the drug has produced survival benefit with antitumor...

  • Science: The Communal Language. LOONEY, WILLIAM // Pharmaceutical Executive;Dec2016, Vol. 36 Issue 12, p3 

    The article focuses on need of financial support for pharmaceutical research. Topics discussed include reason behind high introductory drug prices such as exploitation of government research subsidies, corporate advertising campaign "Before it Became a Medicine" by Pfizer, Food and Drug...

  • US watching pharmaceutical overhaul debate in France. Pecquet, Julian // Hill;6/28/2011, Vol. 18 Issue 94, p10 

    The article reports on the impact of the proposed reforms in the pharmaceutical industry in France on the policy standards of the U.S. Food and Drugs (FDA) regarding its prescription of newly approved drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics